hotspot -WSS

hotspot

author：entertainment 2025-09-27 23:32:13 - browse：968

Human embryonic stem cells Annie Cavanagh/Wellcome Images

The Food and Drug Administration on Thursday unveiled a series of guidelines that aim to encourage the development of promising and legitimate stem cell therapies while distinguishing them from the largely untested stem cell treatments hawked by unregulated clinics around the country.

The FDA’s guidelines have been expected and eagerly awaited by the stem cell community given the rapid proliferation of untested — and potentially unsafe — therapies around the country. Clinics promoting these therapies claim to be able to treat ailments from autism to neurodegenerative disorders to erectile dysfunction.

The guidelines also spell out how the agency will implement the regenerative medicine provisions in a behemoth law enacted last year called the 21st Century Cures Act.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Hepatitis C has a cure — but many Americans still lack access to it
Next article： Medical mystery: When a cough is not just a cough

hotspot

WSS

UnitedHealth argues against case alleging wrongful AI care denials

A disappointing year of Humira biosimilars

Readout LOUD podcast: How biotech is using artificial intelligence

The Readout: Gilead, Bernie Sanders, and other pharma news

The Readout: Gilead, Bernie Sanders, and other pharma news

H5N1 virus can be tracked in retail milk, scientists say

hotspot

hotspot

focus

After affirmative action ruling, medical educators look to 'holistic review'

Vaccine advisory panel ACIP left half staffed by HHS

Novavax promises a turnaround & Lilly roils the obesity market

Readout Newsletter: H5N1 bird flu vaccine, Cytokinetics, Gilead

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Readout Newsletter: Biogen, Rocket Pharma, KalVista, and more

Anesthesiologist group: stop taking Ozempic before surgery

Readout LOUD podcast: How biotech is using artificial intelligence

Moonlake's readout produced a cash windfall. Risks remain

Listen: A conversation with researcher Kevin Esvelt on biosecurity

leisure time

Private equity deals in Medicare Advantage declines

Gilead acquiring CymaBay and its liver disease drug for $4.3 billion

A disappointing year of Humira biosimilars

Medical mystery: When a cough is not just a cough

H5N1 virus can be tracked in retail milk, scientists say

Listen: More tumult at BIO & coercive care for sickle cell patients

hotspot

explore

focus

explore